The Pharmaceutical Market : China

By Author: Bharat Book Bureau
Total Articles: 1486
Comment this article

Lowering drug prices remains a top priority for health authorities. The National Development and Reform Commission (NDRC) implemented two rounds of drug price reductions in 2011, one in March and the other in September. Most of the drugs reduced were manufactured by multinationals, which had previously not been subject to pricing controls. In terms of regulatory developments, the SFDA started to inspect overseas manufacturing facilities in November 2011, as the agency seeks to align its practices with international standards. In July 2011, the MoH revealed that it may introduce mandatory licensing policy to secure cheaper drugs for HIV/AIDS patients, as part of the country’s universal health coverage programme. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-china.html

The highly fragmented drug distribution industry in China continued to see consolidation in 2011. This is part of the government’s 12th Five-Year Plan 2011-2015, to strengthen the national drug distribution industry by actively supporting acquisitions, mergers and reorganisations. There were ...
... a number of competitive strategies completed in the second half of 2011: GPHG acquired Qingdao Likang Pharmaceutical Company and Shandong Hua Wei; Pfizer signed a drug distribution agreement with Jointown; Alliance Boots signed a letter of intent to acquire a stake in Nanjing Pharmaceutical; and Shanghai Pharmaceutical Group strengthened its drug distribution in Northern China through a large capital expenditure.

Espicom projects that the Chinese pharmaceutical market will grow by a moderate double-digit figure between 2012 and 2017. China will be the largest pharmaceutical market in the Asia Pacific region, overtaking Japan in 2016. China will represent over a third of the Asia Pacific region’s total pharmaceutical market in 2017. A number of Chinese pharmaceutical manufacturers have witnessed massive growth in recent years and have expanded their operations both domestically and abroad. The top 10 local pharmaceutical manufacturers, including China Pharmaceutical Group, Harbin Pharmaceutical Group, North China Pharmaceutical and Shanghai Pharmaceuticals, had collective revenue of around US$10.0 billion in 2010.

PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH
Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles
EXECUTIVE SUMMARY.. 1
Snapshot: Strategic Espicom Analysis..2
Snapshot: Key Data Projections3
MACROENVIRONMENT 4
POLITICAL..4
ECONOMIC5
Projections.5
Government’s Revaluation of CNY..6
LEGAL6
Administrative Protection7
USTR Status7
DEMOGRAPHIC.8
Projections.8
Current Figures9
Demographic Indicators9
Births 9
Deaths 9
Infant Deaths. 9
Life Expectancy at Birth 9
EPIDEMIOLOGY.. 10
DISEASE BURDEN..10
Leading Causes of Mortality.10
DISEASE PREVALENCE11
Communicable Diseases.11
HIV/AIDS. 11
Non-communicable Diseases..12
Diabetes. 12
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 13
ORGANISATION..13
Healthcare Reform Plan .13
Ministry of Health13
Hospitals 13
Rural Healthcare.. 14
Red Cross Society of China.14
EXPENDITURE..15
Projections..15
Latest Figures.16
Health Insurance.16
Public Health Insurance. 16
Private Health Insurance 18
INFRASTRUCTURE.18
Hospital Infrastructure18
Outpatient Infrastructure..19
SERVICES. 20
Inpatient Analysis20
Outpatient Analysis..21
WORKFORCE 22
Projections..22
Current State..23
REGULATORY AFFAIRS.. 24
NATIONAL AUTHORITY.24
Department of Drug Registration24
REGULATORY DEVELOPMENTS..24
SFDA Starts Overseas Factory Inspections..24
Revised GMP Regulations..25
Revised Antibiotic Regulations..25
MARKETING REGISTRATION. 25
Department of Drug Safety & Inspection.26
Department of Drug Market Compliance.26
Drug Classification.27
Regulatory Legislation27
2001 DAL Amendments.27
Drug Import Regulation.28
GMP Regulations.28
Drug Approval Process.28
Clinical Trials28
Quality Tests29
Certification.29
PACKAGING.. 29
POST-MARKETING SURVEILLANCE. 30
Revoked Licences30
Bribery Cases.30
PROMOTION 30
Advertising .30
PRICING & REIMBURSEMENT. 31
PRICING 31
National Pricing31
REIMBURSEMENT .32
DISTRIBUTION CHANNELS.. 34
DRUG WHOLESALING 34
Selected Wholesalers35
Alliance Boots35
China Medical System.35
Chindex..35
First China Pharmaceutical Group.36
Global Pharm Holdings Group.. 37
Guangzhou Pharmaceutical 37
Hutchison China MediTech..38
Jointown Pharmaceutical Group.38
Nanjing Pharmaceutical.39
Shanghai Pharmaceuticals..39
Sinopharm40
DRUG RETAILING42
Selected Pharmacy Chains42
China BCT Pharmacy Group 42
ShenZhen Nepstar.42
MARKET ANALYSIS 43
SIZE..43
Projections..43
Historical Figures.45
Current Structure.46
PRODUCT DEVELOPMENT. 48
12th Five-Year Plan 2011-2015.48
Mega New Drug Development Programme..48
SFDA R&D Initiatives.48
Beijing Economic-Technological Development Area49
Zhangjiang Hi-Tech Park.49
MANUFACTURING 50
China to Turn Five Companies into International Producers TRADE52
Exports..52
Imports..55

For more information kindly visit :
The Pharmaceutical Market : China

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/